8 January 2014
Immunocore today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Please click on the link below to download the full Press Release:
Immunocore and MedImmune enter immunotherapy agreement to develop novel cancer therapies
